(Q35615823)

English

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

scientific article published on 26 September 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 August 2017

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia (English)

1 reference

Europe PubMed Central

9 August 2017

0 references

1 reference

based on heuristic

inferred from title

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

12

object named as

Larry J Schaaf

1 reference

Europe PubMed Central

9 August 2017

1

object named as

John C Byrd

1 reference

Europe PubMed Central

9 August 2017

15

object named as

Nyla A Heerema

1 reference

Europe PubMed Central

9 August 2017

3

object named as

James T Dalton

1 reference

Europe PubMed Central

9 August 2017

8

object named as

Kristie A Blum

1 reference

Europe PubMed Central

9 August 2017

Michael R Grever

20

object named as

Michael R Grever

1 reference

Europe PubMed Central

9 August 2017

5

object named as

Mitch A Phelps

1 reference

Europe PubMed Central

9 August 2017

Gerard Lozanski

16

object named as

Gerard Lozanski

1 reference

Europe PubMed Central

9 August 2017

7

object named as

Mollie Moran

1 reference

Europe PubMed Central

9 August 2017

Thomas Lin Pedersen

2

object named as

Thomas S Lin

1 reference

Europe PubMed Central

9 August 2017

Michelle Brooker-McEldowney

10

object named as

Michelle Brooker-McEldowney

1 reference

Europe PubMed Central

9 August 2017

11

object named as

Sarah Broering

1 reference

Europe PubMed Central

9 August 2017

17

object named as

Donn C Young

1 reference

Europe PubMed Central

9 August 2017

author name string

Di Wu

4

1 reference

Europe PubMed Central

9 August 2017

Beth Fischer

6

1 reference

Europe PubMed Central

9 August 2017

Brad Rovin

9

1 reference

Europe PubMed Central

9 August 2017

Amy J Johnson

13

1 reference

Europe PubMed Central

9 August 2017

David M Lucas

14

1 reference

Europe PubMed Central

9 August 2017

Jose-Ramon Suarez

18

1 reference

Europe PubMed Central

9 August 2017

A Dimitrios Colevas

19

1 reference

Europe PubMed Central

9 August 2017

language of work or name

0 references

publication date

26 September 2006

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

109

1 reference

Europe PubMed Central

9 August 2017

399-404

1 reference

Europe PubMed Central

9 August 2017

2

1 reference

Europe PubMed Central

9 August 2017

Inhibitors of cyclin-dependent kinase modulators for cancer therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

12 July 2018

Cell cycle regulatory kinase modulators: interim progress and issues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

12 July 2018

Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

12 July 2018

Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

12 July 2018

Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

12 July 2018

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

12 July 2018

Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

12 July 2018

Leukemic and non-leukemic lymphocytes from patients with Li Fraumeni syndrome demonstrate loss of p53 function, Bcl-2 family dysregulation and intrinsic resistance to conventional chemotherapeutic drugs but not flavopiridol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

12 July 2018

Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

12 July 2018

Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

12 July 2018

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

12 July 2018

Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

12 July 2018

Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

12 July 2018

Flavopiridol inhibits P-TEFb and blocks HIV-1 replication

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

12 July 2018

Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

12 July 2018

Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

12 July 2018

Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

12 July 2018

Determination of flavopiridol (L86 8275; NSC 649890) in human plasma by reversed-phase liquid chromatography with electrochemical detection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

12 July 2018

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

12 July 2018

Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

12 July 2018

The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

12 July 2018

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

12 July 2018

Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

25 September 2018

A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

25 September 2018

High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

25 September 2018

Phase II study of flavopiridol in patients with advanced colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

25 September 2018

Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

25 September 2018

Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

25 September 2018

Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

25 September 2018

A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1785084

25 September 2018

Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/17003373

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic Lymphocytic Leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/17003373

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute tumor lysis syndrome induced by high-dose corticosteroids in a patient with chronic lymphatic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/17003373

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/17003373

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/17003373

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/17003373

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias

1 reference

https://pubmed.ncbi.nlm.nih.gov/17003373

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor lysis syndrome following single-dose mitoxantrone

1 reference

https://pubmed.ncbi.nlm.nih.gov/17003373

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2006-05-020735

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35615823&oldid=1858788034"